Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial by Yu, Jennifer et al.
B
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 5 , N O . 1 2 , 2 0 1 2
© 2 0 1 2 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 2 . 0 7 . 0 1 6Safety and Efficacy of High- Versus Low-Dose
Aspirin After Primary Percutaneous Coronary
Intervention in ST-Segment Elevation
Myocardial Infarction
The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) Trial
Jennifer Yu, MBBS,*† Roxana Mehran, MD,*‡ George D. Dangas, MD, PHD,*‡
immer E. Claessen, MD,‡ Usman Baber, MD,* Ke Xu, PHD,‡ Helen Parise, SCD,‡
artin Fahy, MSC,‡ Alexandra J. Lansky, MD,§ Bernhard Witzenbichler, MD,
Cindy L. Grines, MD,¶ Giulio Guagliumi, MD,# Ran Kornowski, MD,**
Jochen Wöhrle, MD,†† Dariusz Dudek, MD, PHD,‡‡ Giora Weisz, MD,*§§
Gregg W. Stone, MD*§§
New York, New York; New Haven, Connecticut; Detroit, Michigan; Randwick, New South Wales,
Australia; Berlin, and Ulm, Germany; Bergamo, Italy; Petah Tikva, Israel; and Krakow, Poland
Objectives This study sought to examine the relationship between the aspirin dose prescribed at
hospital discharge and long-term outcomes after ST-segment elevation myocardial infarction in pa-
tients treated with primary percutaneous coronary intervention (PCI).
Background Patients with ST-segment elevation myocardial infarction who undergo primary PCI are
prescribed maintenance aspirin doses that vary between 75 and 325 mg daily. Whether the dose of
aspirin affects long-term patient outcomes is unknown.
Methods We compared 3-year outcomes in patients who were prescribed high-dose (200 mg
daily) versus low-dose (200 mg daily) aspirin from the large-scale HORIZONS-AMI (Harmonizing
Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
Results Among 2,851 patients, 2,289 patients (80.3%) were discharged on low-dose aspirin and 562
patients (19.7%) were discharged on high-dose aspirin. Patients discharged on high-dose rather than
low-dose aspirin were more likely to have a history of hypertension, hyperlipidemia, family history of
premature coronary disease, prior treatment with PCI or coronary artery bypass surgery, and to be
enrolled in the United States. Patients discharged on high-dose aspirin had higher 3-year rates of
major adverse cardiovascular events, reinfarction, ischemic target vessel revascularization, major
bleeding, and stent thrombosis. After multivariable analysis, discharge on high-dose aspirin was an
independent predictor of major bleeding (hazard ratio: 2.80; 95% conﬁdence interval: 1.31 to 5.99;
p  0.008), but not of adverse ischemic events.
Conclusions In patients with ST-segment elevation myocardial infarction undergoing primary PCI,
discharge on high-dose rather than low-dose aspirin may increase the rate of major bleeding with-
out providing additional ischemic beneﬁt. (J Am Coll Cardiol Intv 2012;5:1231–8) © 2012 by the
American College of Cardiology Foundation
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1232Whereas the efficacy of aspirin for primary and secondary
revention in patients with coronary artery disease and
cute coronary syndromes (ACS) is well established
1–3), there is uncertainty regarding the optimal dose of
spirin. Currently, daily maintenance doses range between 75
nd 325 mg. Maximal inhibition of thromboxane-mediated
latelet activation is achieved with aspirin doses as low as
0 mg (4), whereas higher doses of aspirin may result in
ncreased bleeding risk, especially from the gastrointes-
inal tract, in part due to dose-dependent inhibition of
astroprotective prostaglandin synthesis (5,6). The ques-
ion regarding aspirin maintenance dose is of renewed
ignificance in the context of the long-term requirement for
ual antiplatelet therapy following percutaneous coronary
ntervention (PCI), the increased bleeding propensity of
ewer, more potent adenosine diphosphate antagonists,
nd possible drug-to-drug interactions (7–9). Recent
CS studies have not shown benefits with higher main-
tenance aspirin doses (9,10). However, the optimal long-
term maintenance dose of aspirin in
patients undergoing primary PCI
for ST-segment elevation myocar-
dial infarction (STEMI) has not
been studied.
Therefore, we assessed 3-year
outcomes from the HORIZONS-
AMI (Harmonizing Outcomes
With Revascularization and Stents
in Acute Myocardial Infarction)
trial according to the discharge
dose of aspirin, with the aim to
examine the impact of aspirin
dose on late outcomes in pa-
tients with STEMI.
Methods
Patient population. The design of the HORIZONS-AMI
rial has been described elsewhere (11,12). In brief,
ORIZONS-AMI was a prospective, large-scale, multi-
enter, 2  2 factorial randomized trial. Patients with
TEMI undergoing primary PCI who presented within
2 h of symptom onset were randomly assigned to receive
ivalirudin versus heparin (unfractionated heparin) plus a
lycoprotein IIb/IIIa inhibitor in a 1:1, open-label fashion.
was funded by Boston Scientific and The Medicines Company. Drs. Mehran and
Dangas have served as consultants to AstraZeneca, Abbott Vascular, Johnson &
Johnson, Merck Sharp & Dohme, and Maya Medical; have served on the advisory
board of Regado; and have received research grants from BMS/Sanofi, Daiichi-
Sankyo/Eli Lilly and Company, and The Medicines Company. Dr. Witzenbichler
has received lecture fees from The Medicines Company and Boston Scientific
Corporation. Dr. Grines has received consultant fees/honoraria/speakers’ fees for
Abbott Vascular, ABIOMED, Daiichi-Sankyo/Eli Lilly and Company, and The
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
CABG  coronary artery
bypass graft
MI  myocardial infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial InfarctionMedicines Company. Dr. Guagliumi has served as a consultant to Boston Scientific
M
after diagnostic coronary angiography, eligible patients under-
ent a secondary 3:1 randomization to the Taxus Express
aclitaxel-eluting stent (Boston Scientific, Natick, Massachu-
etts) versus the Express bare-metal stent (Boston Scientific).
Patients were given a loading dose of aspirin (324 mg
hewable or 500 mg intravenous) in the emergency depart-
ent, a daily dose of 300 to 325 mg/day while in hospital,
nd an indefinite maintenance dose 75 mg/day at dis-
harge at the discretion of the treating physician. A 300- or
00-mg clopidogrel loading dose was given per physician
reference, followed by 75 mg daily for a minimum of 6
onths (12 months recommended).
The institutional review board or ethics committee of all
articipating centers approved the trial protocol and all
atients provided written informed consent.
orporation, St. Jude Medical, and Volcano Corporation and has received research
rants from Abbott Vascular, Boston Scientific Corporation, and St. Jude Medical.
r. Dudek has received research grants from Boston Scientific Corporation, St. Jude
edical, and Volcano Corporation and has served as a consultant to Boston Scientific
orporation and St. Jude Medical. Dr. Stone has served as a consultant to Volcano
orporation. All other authors have reported that they have no relationships relevant
o the contents of this paper to disclose.
3,602 pa ents with STEMI 
enrolled in
HORIZONS-AMI Trial
Study analysis cohort 
N=2,851
Discharge dose aspirin
≤200mg/day
N=2,289
75mg/day, n=665
80-81mg/day, n=271
100mg/day, n=1,355
150mg/day, n=71
160-200mg/day, n=32
Discharge dose aspirin
>200mg/day
N=562
250-300mg/day, n=54
325mg/day, n=501
>325mg, n=7
81 in-hospital mortality
177 no thienopyridine at 
discharge
493 discharge dose of aspirin
unclear
Figure 1. Study Flow Chart
HORIZONS-AMI  Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction; STEMI  ST-segment elevation myo-
cardial infarction.anuscript received May 10, 2012; revised manuscript received June 26, 2012,
ccepted July 4, 2012.
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1233Clinical endpoints and deﬁnitions. The primary endpoints
of HORIZONS-AMI have been reported (11,12). Major
bleeding not related to coronary artery bypass graft (CABG)
included: intracranial or intraocular hemorrhage; access site
hematoma with diameter 5 cm, or one requiring inter-
vention; overt bleeding with hemoglobin decrease 3 g/dl,
or any hemoglobin decrease 4 g/dl; bleeding requiring
reoperation; and blood transfusion. Net adverse clinical
events were a composite of non-CABG–related major
bleeding and major adverse cardiovascular events, including
death, reinfarction, target vessel revascularization for is-
chemia, and stroke. Stent thrombosis was defined as defi-
nite or probable by Academic Research Consortium criteria
Table 1. Baseline Patient Characteristics
Characteristic
Age, yrs
Male sex
Enrollment in the United States (vs. outside the United Stat
Race
White
Black
Asian
Hispanic
Other
BMI, kg/m2
Medical history
Hypertension
Hyperlipidemia
Current smoker
Diabetes mellitus
Treated with insulin
Prior MI
Prior PCI
Prior CABG
Family history of premature
CAD
Angina
CHF
Atrial ﬁbrillation or ﬂutter
Peripheral vascular disease
Chronic kidney disease on dialysis
Characteristics at presentation
Killip class 1
Anemia*
Creatinine clearance 60†
LVEF—site reported, %
LVEF 40%—site reported
Values are % (n/N) or median [IQR]. *Anemia is defined as baseline hem
by the Cockroft-Gault formula.
BMI bodymass index; CABG coronary artery bypass graft; CADrange; LVEF left ventricular ejection fraction; MImyocardial infarction; PC(13). All events were adjudicated by an independent clinical
events committee blinded to treatment assignment.
Present analysis. For the current study, high-dose aspirin
as defined as a discharge dose 200 mg daily. Low-dose
spirin was defined as a discharge dose 200 mg daily. Of
he 3,602 patients enrolled in the HORIZONS-AMI trial,
e excluded 81 patients due to in-hospital mortality, 95
atients who were discharged on no aspirin, 177 patients
ischarged on no thienopyridine, and 398 patients for whom
he aspirin discharge dose was uncertain. The baseline charac-
eristics and out-of-hospital outcomes in the remaining 2,851
atients were examined according to the prescription of high-
ose versus low-dose aspirin at discharge (Fig. 1).
Aspirin Discharge
Dose <200 mg
(n  2,289)
Aspirin Discharge
Dose >200 mg
(n  562) p Value
59.9 [52.6, 69.2] 58.8 [50.8, 68.5] 0.03
76.3 (1,747/2,289) 79.4 (446/562) 0.11
10.4 (238/2,289) 81.9 (460/562) 0.0001
96.0 (2,197/2,289) 84.3 (474/562) 0.0001
0.7 (16/2,289) 7.3 (41/562) 0.0001
0.7 (16/2,289) 0.7 (4/562) 0.99
2.5 (57/2,289) 6.8 (38/562) 0.0001
0.1 (3/2,289) 0.9 (5/562) 0.01
27.0 [24.5, 30.0] 27.9 [25.0, 31.5] 0.0002
50.6 (1,158/2,289) 58.2 (327/562) 0.001
42.3 (968/2,289) 47.9 (269/562) 0.02
65.0 (1,482/2,280) 63.5 (357/562) 0.13
16.6 (380/2,289) 15.8 (89/562) 0.66
4.7 (107/2,289) 4.4 (25/562) 0.82
10.6 (243/2,289) 11.0 (62/562) 0.77
10.0 (228/2,289) 13.2 (74/562) 0.03
2.5 (57/2,289) 4.1 (23/562) 0.04
29.1 (667/2,289) 33.8 (190/562) 0.03
24.3 (556/2,289) 14.9 (84/562) 0.0001
2.5 (58/2,289) 2.8 (16/562) 0.68
1.7 (38/2,289) 1.4 (8/562) 0.69
4.5 (103/2,288) 2.8 (16/562) 0.08
0.2 (4/2,288) 0.0 (0/562) 0.99
8.3 (189/2,286) 7.3 (41/562) 0.45
10.2 (219/2,148) 12.4 (69/555) 0.13
14.9 (315/2,108) 16.6 (89/536) 0.34
50 [45, 60] 50 [40, 55] 0.0001
12.9 (255/1,973) 17.7 (86/487) 0.007
t39 for men,36 for women. †Creatinine clearance was calculated
ary artery disease; CHF congestive heart failure; IQR interquartilees)
atocri
 coronI percutaneous coronary intervention.
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1234Statistical analyses. All analyses are by intention to treat.
ategorical variables were compared using chi-square or
isher exact test, and continuous variables were compared
sing the Wilcoxon rank-sum test. A propensity score was
eveloped using a logistic regression model with high-
ersus low-aspirin discharge dose as a dependent variable
nd the following factors as independent variables: age; sex;
ace; enrollment in versus outside the United States; body
ass index; hypertension; current smoking; diabetes; ane-
ia; platelet count; white cell count; creatinine clearance;
ost-PCI TIMI (Thrombolysis In Myocardial Infarction)
ow grade 3 versus 3 flow; pre-randomization heparin;
ssignment to bivalirudin versus unfractionated heparin 
lycoprotein IIb/IIIa inhibitor; radial versus femoral access;
Table 2. Procedural Data, Medications, and In-Hospit
A
Assignment to bivalirudin (vs. UFH  GPI) 5
Radial access
Primary management strategy
Primary PCI 9
Deferred PCI
CABG without PCI (through 30 days)
Medical management only (through 30 days)
PCI cohort
Assignment to Taxus PES (vs. BMS) 7
Total stent length implanted, mm
Multiple vessels treated
Multiple lesions treated
Total ﬂuoroscopy time, min
Total amount of contrast, ml 2
LAD infarct-related artery (per vessel) 4
Post-PCI TIMI ﬂow grade 3 (per vessel) 9
Symptom onset to ﬁrst balloon inﬂation, min 2
Door-to-balloon time, min 1
Length of hospitalization, days
In-hospital events
Reinfarction
Ischemic TVR
Stroke
Major bleeding (non-CABG related)
Stent thrombosis
Discharge medications
Beta blockers 9
Coumadin
ACE-I or ARB 8
Statin 9
Values are % (n/N) or median [IQR].
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angioten
inhibitor; LAD left anterior descending artery; PES paclitaxel-elutrevascularization; UFH unfractionated heparin; other abbreviations as in Taischarge prescription of beta blockers, angiotensin convert-
ng enzyme-inhibitors or angiotensin receptor blockers, and
tatins; and thienopyridine discontinuation within the first 6
onths, 1, 2, or 3 years. A set of significant variables was
elected using an entry and exit level of significance of 0.10,
nd a propensity score was determined. Cox proportional
azard models were used to predict time-to-event outcomes
sing high- versus low-aspirin discharge dose and the
ropensity score as covariates, and compared with the log-rank
est. These models were used to determine the predicted
urvival rates at the actual event times in each group and to
enerate the adjusted time-to-event curves. All statistical anal-
ses were performed with SAS (version 9.2, SAS Institute Inc.,
ary, North Carolina).
nts
Discharge
200 mg
2,289)
Aspirin Discharge
Dose >200 mg
(n  562) p Value
172/2,289) 49.1 (276/562) 0.37
5/2,289) 0.5 (3/562) 0.0001
235/2,289) 98.2 (552/562) 0.41
2,289) 0.0 (0/562) 0.99
2,289) 0.2 (1/562) 0.70
/2,289) 1.6 (9/562) 0.66
558/2,073) 75.3 (368/489) 0.96
8.0, 36.0] 28.0 [20.0, 40.0] 0.002
/2,213) 3.5 (19/546) 0.42
6/2,213) 10.8 (59/546) 0.47
.0, 16.0] 13.0 [9.0, 19.0] 0.0001
78.0, 288.0] 240.0 [190.0, 300.0] 0.0001
3/2,422) 37.1 (219/590) 0.12
241/2,417) 93.6 (552/590) 0.48
62.0, 335.0] 206.5 [148.0, 310.0] 0.001
5.0, 138.0] 89.0 [70.0, 124.0] 0.0001
.0, 7.0] 3.0 [3.0, 5.0] 0.0001
/2,289) 1.4 (8/562) 0.34
/2,289) 1.6 (9/562) 0.78
2,289) 0.5 (3/562) 0.46
1/2,289) 10.3 (58/562) 0.0001
/2,188) 1.1 (6/534) 0.71
104/2,289) 92.2 (518/562) 0.84
/2,288) 3.9 (22/562) 0.33
958/2,288) 68.5 (385/562) 0.0001
210/2,288) 92.9 (522/562) 0.0001
ceptor blocker; BMS  bare-metal stents; GPI  glycoprotein IIb/IIIa
ts; TIMI Thrombolysis In Myocardial Infarction; TVR target vesselal Eve
spirin
Dose <
(n 
1.2 (1,
8.1 (18
7.6 (2,
0.0 (1/
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24.0 [1
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11.0 [7
24.0 [1
0.6 (98
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25.0 [1
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1235Results
Patient characteristics and treatment. Among 2,851 pa-
tients, 2,289 (80.3%) were discharged on low-dose aspirin
(200 mg/day) and 562 patients (19.7%) were discharged
on high-dose aspirin (200 mg/day) (Fig. 1). Patients
discharged on high-dose versus low-dose aspirin were more
likely to have a history of hypertension, hyperlipidemia,
prior PCI or CABG, family history of premature coronary
disease, and to be enrolled in the United States (Table 1).
Treatment assignments were similar between the 2 groups
(Table 2). With respect to PCI variables, patients on
high-dose compared with low-dose aspirin had more fem-
oral (vs. radial) access, longer total stent length, longer
fluoroscopy time, and more contrast volume, but also had
shorter symptom-onset- and door-to-first-balloon inflation
time. The proportion of patients who had final TIMI flow
grade 3 following PCI was similar in the 2 groups. Patients
maintained on high-dose aspirin were, however, less likely
to have an angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker, or statin prescribed on dis-
charge, and had a higher incidence of major bleeding before
discharge. The use of Coumadin was balanced between the
2 groups.
Post-discharge antiplatelet therapy and clinical outcomes.
From 1-year follow-up, patients on high-dose aspirin were
more likely to continue with thienopyridine therapy than
were patients on low-dose aspirin (Table 3). There was no
significant difference in the rates of aspirin use between the
2 groups during the 3-year follow-up. Patients discharged
on high-dose aspirin had significantly higher rates of major
adverse cardiovascular events, reinfarction, target vessel
Table 3. Antiplatelet Use Following Discharge
Low-Dose Aspirin High-Dose Aspirin p Value
30 days
Aspirin 98.7 (2,198/2,228) 99.1 (539/544) 0.42
Thienopyridine 98.6 (2,197/2,229) 98.2 (535/545) 0.49
6 months
Aspirin 97.8 (2,130/2,177) 98.2 (504/513) 0.56
Thienopyridine 91.5 (1,993/2,179) 92.4 (474/513) 0.49
1 year
Aspirin 97.4 (2,111/2,168) 96.1 (470/489) 0.13
Thienopyridine 69.2 (1,502/2,171) 76.9 (376/489) 0.0007
2 years
Aspirin 96.8 (2,073/2,142) 95.1 (462/486) 0.06
Thienopyridine 32.1 (690/2,148) 61.5 (299/486) 0.0001
3 years
Aspirin 96.2 (2,004/2,083) 94.7 (443/468) 0.13
Thienopyridine 23.0 (480/2,089) 56.2 (263/468) 0.0001
Values are % (n/N).revascularization, non-CABG–related major bleeding, netadverse clinical events, and definite or probable stent throm-
bosis (Table 4).
After propensity score–adjusted multivariable analysis,
high-dose aspirin was an independent predictor of non-
CABG–related major bleeding, but not of adverse ischemic
outcomes (Table 5, Fig. 2A). The increase in major bleed-
ing in patients treated with high-dose rather than low-dose
aspirin emerged in the first 2 months after hospital dis-
charge, although excess events continued to accrue in the
high-dose aspirin group over the entire 3-year follow-up
period (Fig. 2B). There was no significant interaction
between enrollment within versus outside the United States
and aspirin dose on adverse ischemic and bleeding end-
points (Table 6). Formal interaction testing also showed no
significant effect of the duration of thienopyridine use on
the increased risk of major bleeding with high-dose versus
low-dose aspirin (p  0.63).
Additional sensitivity analyses showed consistent results.
Comparing 3-year outcomes in 262 propensity-matched
pairs led to no qualitative changes in the study results (data
not shown). In addition, the results remained essentially
unchanged when: 1) the propensity score–adjusted multi-
variable analysis was repeated with a new propensity score
that did not include thienopyridine use duration; and when
2) additional variables (thienopyridine discontinuation as a
Table 4. Post-Discharge 3-Year Clinical Outcomes
Aspirin Discharge
Dose <200 mg
(n  2,289)
Aspirin Discharge
Dose >200 mg
(n  562) p Value
MACE 17.5 (391) 23.8 (125) 0.0009
Mortality 4.1 (92) 5.0 (26) 0.39
Cardiac mortality 1.8 (39) 2.1 (11) 0.58
Reinfarction 5.7 (124) 8.6 (44) 0.01
Ischemic TVR 11.3 (249) 15.4 (80) 0.01
Stroke 1.2 (26) 1.7 (9) 0.31
Ischemic 1.1 (23) 1.7 (9) 0.18
Hemorrhagic 0.1 (3) 0.0 (0) 0.40
Major bleeding (non-CABG
related)
1.6 (34) 6.5 (33) 0.0001
NACE 18.3 (408) 26.4 (139) 0.0001
TIMI bleeding
Major 0.8 (18) 2.3 (12) 0.003
Minor 0.4 (8) 1.1 (6) 0.02
Major or minor 1.2 (26) 3.5 (18) 0.0002
GUSTO bleeding
Severe/life-threatening 0.3 (7) 0.6 (3) 0.37
Moderate 1.2 (26) 5.3 (27) 0.0001
Mild 0.3 (6) 1.1 (6) 0.01
Deﬁnite or probable stent
thrombosis
63 (3.0) 27 (5.4) 0.007
Values are Kaplan-Meier estimated % (n).
GUSTO Global Use of Strategies to Open Occluded Arteries; MACEmajor adverse cardio-
vascular events, including death, reinfarction, TVR for ischemia, stroke; NACE  net adverseclinical events, including MACE or major bleeding; other abbreviations as in Tables 1 and 2.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 2 , 2 0 1 2
D E C E M B E R 2 0 1 2 : 1 2 3 1 – 8
Yu et al.
Aspirin Dose After Acute MI
1236time-dependent covariate, prior MI or CABG and Killip
class at presentation) were included along with the propen-
sity score in the Cox model.
Discussion
In the present analysis from the HORIZONS-AMI trial,
after adjustment for baseline and procedural differences,
patients undergoing primary PCI for STEMI discharged on
and maintained chronically on high-dose aspirin had similar
long-term rates of adverse ischemic events but significantly
more major bleeding than did patients on low-dose aspirin.
Therefore, this analysis contributes to an increasing litera-
ture that suggests that patients with ACS (both STEMI
and non-STEMI) and those undergoing PCI should be
maintained on low-dose rather than high-dose aspirin.
Most, but not all prior studies support the results of the
present analysis. Post-hoc analyses from the CURE (Clopi-
dogrel in Unstable Angina To Prevent Recurrent Events)
and the BRAVO (Blockade of the Glycoprotein IIb/IIIa
Receptor to Avoid Vascular Occlusion) trials showed in-
creased rates of bleeding rates in patients taking higher
versus lower aspirin maintenance dose at long-term follow-
up, without concordant reductions in their respective pri-
mary study endpoint, composite ischemic events (14,15). A
similar result was reported in a meta-analysis by Serebruany
et al. (16). However, other meta-analyses showed no differ-
ence in bleeding rates whether higher or lower aspirin
maintenance doses were used (1,17). In the CURRENT-
OASIS 7 (Clopidogrel and Aspirin Optimal Dose Usage to
Reduce Recurrent Events-Seventh Organization to Assess
Strategies in Ischemic Symptoms) trial, in which patients
with ACS were randomized to high-dose (300 to 325 mg)
Table 5. Hazard of Post-Discharge Outcomes With High- vs. Low-Dose
Aspirin
Unadjusted Adjusted*
HR (95% CI) p Value HR (95% CI) p Value
MACE 1.41 (1.15–1.72) 0.0009 1.14 (0.83–1.56) 0.41
Mortality 1.20 (0.78–1.89) 0.39 0.85 (0.43–1.69) 0.64
Reinfarction 1.54 (1.09–2.17) 0.01 0.92 (0.55–1.55) 0.76
Mortality or reinfarction 1.39 (1.05–1.82) 0.02 0.89 (0.58–1.37) 0.61
Ischemic TVR 1.39 (1.08–1.79) 0.01 1.18 (0.81–1.72) 0.39
Stroke 1.49 (0.69–3.13) 0.31 1.07 (0.32–3.53) 0.92
Major bleeding
(non-CABG–related)
4.17 (2.63–6.67) 0.0001 2.80 (1.31–5.99) 0.008
NACE 1.52 (1.25–1.85) 0.0001 1.21 (0.90–1.62) 0.22
Deﬁnite or probable stent
thrombosis
1.85 (1.18–2.94) 0.007 1.23 (0.64–2.37) 0.54
*Propensity score–adjusted. C-statistic for the propensity score discrimination of aspirin dose
groups was 0.9.
CI confidence interval; HR hazard ratio; other abbreviations as in Tables 1, 2, and 4.versus low-dose (75 to 100 mg) aspirin, there were nosignificant differences in the 30-day rates of major bleeding
or the composite endpoint of cardiac death, MI, or stroke
(10). However, all patients in this trial received a 300-mg
loading dose of aspirin, which may have diminished the
ability for differences to emerge given the short follow-up
duration. In light of these conflicting results, the recent
2011 consensus guidelines for PCI give a new class IIa
recommendation, that it is reasonable to use 81 mg/day
maintenance aspirin dose instead of higher doses (18).
In the present study, there were numerous differences in
baseline demographics and treatments between patients
discharged on high-dose versus low-dose aspirin. Impor-
tantly, most patients maintained on high-dose aspirin were
enrolled in the United States. This is consistent with
O
ut
 o
f H
os
pi
ta
l M
A
CE
 (%
) 
0 
5 
10 
15 
20 
25 
Time in Months 
0 3 6 9 12 15 18 21 24 27 30 33 36 
High Dose Aspirin (> 200mg) 
Low Dose Aspirin (≤ 200mg) 
HR: 1.14 [95%CI 0.83, 1.56] 
P = 0.41 
20.5% 
18.0% 
O
ut
 o
f H
os
pi
ta
l N
on
-C
A
BG
 M
aj
or
 B
le
ed
in
g 
(%
) 
0 
1 
2 
3 
4
5 
Time in Months 
0 3 6 9 12 15 18 21 24 27 30 33 36 
High Dose Aspirin (> 200mg) 
Low Dose Aspirin (≤ 200mg) 
HR: 2.80 [95%CI 1.31, 5.99] 
P = 0.008 
4.5% 
1.6% 
A
B
Figure 2. 3-year Clinical Outcomes
Three-year, propensity score–adjusted time-to-event curves for out-of-
hospital (A) major adverse cardiovascular events (MACE) and (B) major
bleeding. CABG  coronary artery bypass graft; CI  conﬁdence interval;
HR  hazard ratio.
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1237previously reported geographic trends in aspirin prescribing
(19) and reflects discrepancies in local treatment guidelines
(20–23). Notably, patients in the high-dose aspirin group
also had a less favorable cardiovascular risk profile and (for
unclear reasons) lower prescription rates of statins,
angiotensin-converting enzyme inhibitors, and angiotensin
receptor blockers. They were also more likely to continue
with a thienopyridine beyond 1 year after STEMI. Again,
regional patient characteristics and prescribing patterns may
in part explain these differences.
After adjusting for these differences, discharge aspirin
dose did not affect long-term ischemic endpoints in this
high-risk population, a finding that is consistent with most
prior studies in which aspirin was combined with clopi-
dogrel (1,14,24). However, in the PLATO (Platelet Inhi-
bition and Patient Outcomes) trial (9), the lowest 1-year
rates of cardiovascular death, MI, or stroke were noted in
patients with ACS treated with ticagrelor and low-dose
aspirin, whereas the highest rates occurred in those treated
with ticagrelor and high-dose aspirin. Ischemic event rates
were intermediate in patients discharged on clopidogrel and
either low-dose or high-dose aspirin, with no significant
differences between these groups. Thus, the PLATO results
are consistent with the present analysis, in which almost all
patients were discharged on clopidogrel (a few on ticlopi-
dine, but none on prasugrel or ticagrelor). Whether there
truly is an interaction between aspirin dose and ticagrelor
deserves further study.
In the current analysis, high-dose aspirin was an inde-
Table 6. Post-Discharge 3-Year Outcomes According
Region Aspirin <200 mg A
MACE US 21.7%
OUS 16.9%
Mortality US 7.4%
OUS 3.9%
Reinfarction US 7.2%
OUS 5.4%
Mortality or reinfarction US 13.5%
OUS 8.9%
Stroke US 2.2%
OUS 1.2%
TVR US 11.0%
OUS 10.9%
Stent thrombosis US 4.2%
OUS 2.9%
Major bleeding US 3.5%
(Not related to CABG) OUS 1.4%
NACE US 23.4%
OUS 17.5%
Values are Kaplan-Meier estimated.
OUS outside the United States; US United States; other abbrevpendent predictor of major bleeding. In contrast, in aPLATO there was no significant difference in bleeding rates
between patients enrolled within versus outside the United
States (9), nor according to aspirin dose, with either
concomitant clopidogrel or ticagrelor treatment (25). In
part, this disparity may be explained by differences in patient
selection criteria, bleeding definitions, or rates between the
2 trials. Also, the high-dose aspirin group in PLATO was
quite small, and in neither trial was aspirin dose random-
ized, leading to the possibility for unmeasured confounders
or chance findings. In CURRENT-OASIS 7, there was no
significant difference in the secondary endpoint of 30-day
major bleeding between the high- and low-dose aspirin
arms in the overall cohort of 25,000 patients or in the
pre-specified subgroup of patients treated with PCI (10,24).
Rates of cardiovascular events were numerically lower
among patients on high- versus low-dose aspirin, but this
was not significant (4.2% vs. 4.4%, p  0.61) (10). How-
ever, significant increases in major gastrointestinal bleeding
and minor bleeding were observed in the higher dose aspirin
group in this trial (10), adding credence to the hypothesis
that high-dose aspirin indeed increases the risk of bleeding
in patients with ACS and in those undergoing PCI, without
providing additional protection from adverse ischemic
events.
Study limitations. As a post-hoc analysis, the findings from
he present study are exploratory and should be considered
ypothesis-generating. Data regarding changes in aspirin
ose after discharge, use of enteric-coated formulations of
spirin and coprescription of nonsteroidal anti-inflammatory
pirin Dose and Region of Enrollment
>200 mg HR (95% CI) p Value p Interaction
3.9% 0.88 (0.63–1.23) 0.45 0.62
3.2% 0.76 (0.50–1.15) 0.20
5.6% 1.34 (0.72–2.48) 0.35 0.44
4.5% 0.87 (0.35–2.14) 0.76
9.7% 0.72 (0.40–1.27) 0.25 0.12
2.7% 1.99 (0.63–6.26) 0.23
4.2% 0.93 (0.61–1.43) 0.75 0.49
7.2% 1.25 (0.61–2.53) 0.54
2.2% 0.98 (0.33–2.86) 0.97 0.82
0.9% 1.27 (0.17–9.41) 0.81
4.4% 0.75 (0.47–1.19) 0.22 0.89
5.4% 0.69 (0.42–1.12) 0.13
5.9% 0.70 (0.31–1.56) 0.38 0.62
3.1% 0.90 (0.28–2.88) 0.86
7.0% 0.50 (0.23–1.09) 0.07 0.26
4.8% 0.30 (0.11,–0.76) 0.008
6.7% 0.84 (0.61–1.16) 0.29 0.60
3.2% 0.73 (0.49–1.09) 0.12
s in Tables 1, 2, 4, and 5.to As
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2gents were not collected in the case report form. Even
(
t
f
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 2 , 2 0 1 2
D E C E M B E R 2 0 1 2 : 1 2 3 1 – 8
Yu et al.
Aspirin Dose After Acute MI
1238propensity-adjusted analyses cannot correct for unmeasured
confounders. Whereas the present study supports the use of
low-dose maintenance aspirin after PCI in ACS, only a
large-scale, randomized trial can definitively address this
issue.
Conclusions
In the current study, we found no difference in ischemic
endpoints between high- and low-dose aspirin used in
combination with clopidogrel, but high-dose aspirin was an
independent predictor for higher rates of major bleeding.
Thus, absent a demonstrated benefit of high-dose aspirin in
patients on dual antiplatelet therapy with clopidogrel fol-
lowing PCI, and given the concern of potential harm of
high-dose aspirin used with more potent P2Y12 inhibitors
i.e., prasugrel and ticagrelor), these data support the rou-
ine use of low-dose aspirin (200 mg daily) at discharge
ollowing primary PCI in STEMI.
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